UNLABELLED: SUMMARY BACKGROUND AND OBJECTIVES: he management of patients with severe hemophilia A and inhibitors to factor VIII (FVIII) resistant to standard immune tolerance is challenging. There have been recent case reports of the successful use of rituximab in up to 57% of patients as part of rescue immune tolerance regimens. Because case reports and small series are prone to the potential bias of reporting good outcomes and relatively short follow up, a consecutive cohort of all patients treated in the UK with prolonged follow up was analyzed. METHODS: A national survey of all Comprehensive Care Haemophilia Center in the UK. RESULTS: A total of 15 patients were reported of whom six (40%) achieved a negative inhibitor titer by Bethesda assay. Durable responses were unusual, observed in only 14% of cases. Clinically significant responses with either a negative inhibitor or an inhibitor titer < 5 BU mL(-1) and no spontaneous bleeding with FVIII replacement were observed in seven (47%) cases. Concomitant use of FVIII appeared to be important. Of the 12 patients treated with rituximab and FVIII, six (50%) achieved a negative inhibitor titer and seven (58%) had a clinically beneficial response. None of the three patients treated without FVIII responded. CONCLUSIONS: These data suggest that the use of rituximab combined with FVIII is a potentially useful treatment for patients with inhibitors resistant to standard immune tolerance, although sustained inhibitor eradication is uncommon.
UNLABELLED: SUMMARY BACKGROUND AND OBJECTIVES: he management of patients with severe hemophilia A and inhibitors to factor VIII (FVIII) resistant to standard immune tolerance is challenging. There have been recent case reports of the successful use of rituximab in up to 57% of patients as part of rescue immune tolerance regimens. Because case reports and small series are prone to the potential bias of reporting good outcomes and relatively short follow up, a consecutive cohort of all patients treated in the UK with prolonged follow up was analyzed. METHODS: A national survey of all Comprehensive Care Haemophilia Center in the UK. RESULTS: A total of 15 patients were reported of whom six (40%) achieved a negative inhibitor titer by Bethesda assay. Durable responses were unusual, observed in only 14% of cases. Clinically significant responses with either a negative inhibitor or an inhibitor titer < 5 BU mL(-1) and no spontaneous bleeding with FVIII replacement were observed in seven (47%) cases. Concomitant use of FVIII appeared to be important. Of the 12 patients treated with rituximab and FVIII, six (50%) achieved a negative inhibitor titer and seven (58%) had a clinically beneficial response. None of the three patients treated without FVIII responded. CONCLUSIONS: These data suggest that the use of rituximab combined with FVIII is a potentially useful treatment for patients with inhibitors resistant to standard immune tolerance, although sustained inhibitor eradication is uncommon.
Authors: Y Dargaud; A Pavlova; S Lacroix-Desmazes; K Fischer; M Soucie; S Claeyssens; D W Scott; R d'Oiron; G Lavigne-Lissalde; G Kenet; C Escuriola Ettingshausen; A Borel-Derlon; T Lambert; G Pasta; C Négrier Journal: Haemophilia Date: 2016-01 Impact factor: 4.287
Authors: A Antun; P E Monahan; M J Manco-Johnson; M U Callaghan; M Kanin; C Knoll; S L Carpenter; J A Davis; M F Guerrera; R Kruse-Jarres; M V Ragni; C Witmer; C E McCracken; C L Kempton Journal: J Thromb Haemost Date: 2015-10-20 Impact factor: 5.824
Authors: Moanaro Biswas; Geoffrey L Rogers; Alexandra Sherman; Barry J Byrne; David M Markusic; Haiyan Jiang; Roland W Herzog Journal: Thromb Haemost Date: 2016-09-29 Impact factor: 5.249
Authors: C Leissinger; C D Josephson; S Granger; B A Konkle; R Kruse-Jarres; M V Ragni; J M Journeycake; L Valentino; N S Key; J C Gill; K R McCrae; E J Neufeld; C Manno; L Raffini; K Saxena; M Torres; V Marder; C M Bennett; S F Assmann Journal: Thromb Haemost Date: 2014-06-12 Impact factor: 5.249
Authors: Giovanni D'arena; Elvira Grandone; Matteo N D Di Minno; Pellegrino Musto; Giovanni Di Minno Journal: Blood Transfus Date: 2015-09-03 Impact factor: 3.443
Authors: Suhrad G Banugaria; Sean N Prater; Judeth K McGann; Jonathan D Feldman; Jesse A Tannenbaum; Carrie Bailey; Renuka Gera; Robert L Conway; David Viskochil; Joyce A Kobori; Amy S Rosenberg; Priya S Kishnani Journal: Genet Med Date: 2012-10-11 Impact factor: 8.822